Shopping Cart 0
Cart Subtotal
AED 0

National Cancer Institute US - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

National Cancer Institute US (NCI), a subsidiary of National Institutes of Health is a provider of cancer research and training services. The institute coordinates National Cancer Program that supports and coordinates research projects in universities, hospitals, research foundations and businesses, and conducts through research grants and cooperative agreements. NCI also supports education and training fundamental sciences and clinical disciplines for holding in basic and clinical research programs and treatment programs related to cancer through career awards, training grants and fellowships. The institute's target therapy areas include leukemia, lymphoma, blood cancer, lung cancer, breast cancer, colorectal cancer and skin cancer, among others. NCI is headquartered in Bethesda, Maryland, the US.

National Cancer Institute US-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment Deals By Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Medical Equipment, Deals By Market, 2012 to YTD 2018 8

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

National Cancer Institute US, Medical Equipment, Deal Details 10

Partnerships 10

GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 10

Pandomedx Enters Into Collaboration with National Cancer Institute 11

Immunovia to Enter into Agreement with National Cancer Institute 12

DiaCarta Enters into Agreement with National Cancer Institute 13

OncoTAb Enters into Agreement with National Cancer Institute 14

SeraCare Life Sciences Enters into R&D Agreement with National Cancer Institute 15

CvergenX Enters Into Co-Development Agreement With National Cancer Institute 16

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 17

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 18

National Cancer Institute US-Key Competitors 19

National Cancer Institute US-Key Employees 20

National Cancer Institute US-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Corporate Communications 23

Oct 18, 2017: Norman Sharpless sworn in as director of the National Cancer Institute 23

Government and Public Interest 24

Jun 05, 2018: TAILORx Guides Adjuvant Chemotherapy in Breast Cancer 24

Product News 26

Sep 26, 2017: NCI-funded TMIST study compares 2-D and 3-D mammography for finding breast cancers 26

Feb 07, 2017: New assay shows promise to advance personalized therapy for cancer patients 27

Other Significant Developments 28

Apr 25, 2018: Kaiser Permanente Scientists Awarded USD 32 Million to Improve Cancer Screening 28

Mar 15, 2018: Care Progress Awarded National Cancer Institute SBIR Fast Track 30

Feb 20, 2018: New imaging technology may help predict aggressiveness of lung cancer 31

Jan 08, 2018: NCI Awards ICF Two Major BPAs to Support Cancer Content, Communications and Web Development Activities 33

Dec 11, 2017: Ochsner Health System Joins BSWRI and TGen to Explore Early Detection Test for Pancreatic Cancer 34

Jun 07, 2017: Caris Life Sciences, National Cancer Institute and ECOG-ACRIN Collaborate to Molecularly Identify Candidates for the NCI-MATCH Clinical Trial 36

May 23, 2017: Sylvester Associate Director Receives USD 2.5 Million Grant for Predictive Testing of Ocular Melanoma 37

Apr 04, 2017: USD 3.6 million to fund personalized 3-D brain maps to guide neurosurgeries 38

Mar 14, 2017: NCI Selects ATCC To Provide End-To-End Cancer Epidemiology Services 40

Feb 02, 2017: Protagen join forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

National Cancer Institute US, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment, Deals by Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Medical Equipment, Deals by Market, 2012 to YTD 2018 8


List Of Table

List of Tables

National Cancer Institute US, Medical Equipment, Key Facts 2

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment Deals By Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Deals By Market, 2012 to YTD 2018 8

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 10

Pandomedx Enters Into Collaboration with National Cancer Institute 11

Immunovia to Enter into Agreement with National Cancer Institute 12

DiaCarta Enters into Agreement with National Cancer Institute 13

OncoTAb Enters into Agreement with National Cancer Institute 14

SeraCare Life Sciences Enters into R&D Agreement with National Cancer Institute 15

CvergenX Enters Into Co-Development Agreement With National Cancer Institute 16

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 17

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 18

National Cancer Institute US, Key Competitors 19

National Cancer Institute US, Key Employees 20

National Cancer Institute US, Other Locations 22

National Cancer Institute US, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

National Cancer Institute US, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

National Cancer Institute US (NCI), a subsidiary of National Institutes of Health is a provider of cancer research and training services. The institute coordinates National Cancer Program that supports and coordinates research projects in universities, hospitals, research foundations and businesses, and conducts through research grants and cooperative agreements. NCI also supports education and training fundamental sciences and clinical disciplines for holding in basic and clinical research programs and treatment programs related to cancer through career awards, training grants and fellowships. The institute's target therapy areas include leukemia, lymphoma, blood cancer, lung cancer, breast cancer, colorectal cancer and skin cancer, among others. NCI is headquartered in Bethesda, Maryland, the US.

National Cancer Institute US-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment Deals By Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Medical Equipment, Deals By Market, 2012 to YTD 2018 8

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

National Cancer Institute US, Medical Equipment, Deal Details 10

Partnerships 10

GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 10

Pandomedx Enters Into Collaboration with National Cancer Institute 11

Immunovia to Enter into Agreement with National Cancer Institute 12

DiaCarta Enters into Agreement with National Cancer Institute 13

OncoTAb Enters into Agreement with National Cancer Institute 14

SeraCare Life Sciences Enters into R&D Agreement with National Cancer Institute 15

CvergenX Enters Into Co-Development Agreement With National Cancer Institute 16

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 17

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 18

National Cancer Institute US-Key Competitors 19

National Cancer Institute US-Key Employees 20

National Cancer Institute US-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Corporate Communications 23

Oct 18, 2017: Norman Sharpless sworn in as director of the National Cancer Institute 23

Government and Public Interest 24

Jun 05, 2018: TAILORx Guides Adjuvant Chemotherapy in Breast Cancer 24

Product News 26

Sep 26, 2017: NCI-funded TMIST study compares 2-D and 3-D mammography for finding breast cancers 26

Feb 07, 2017: New assay shows promise to advance personalized therapy for cancer patients 27

Other Significant Developments 28

Apr 25, 2018: Kaiser Permanente Scientists Awarded USD 32 Million to Improve Cancer Screening 28

Mar 15, 2018: Care Progress Awarded National Cancer Institute SBIR Fast Track 30

Feb 20, 2018: New imaging technology may help predict aggressiveness of lung cancer 31

Jan 08, 2018: NCI Awards ICF Two Major BPAs to Support Cancer Content, Communications and Web Development Activities 33

Dec 11, 2017: Ochsner Health System Joins BSWRI and TGen to Explore Early Detection Test for Pancreatic Cancer 34

Jun 07, 2017: Caris Life Sciences, National Cancer Institute and ECOG-ACRIN Collaborate to Molecularly Identify Candidates for the NCI-MATCH Clinical Trial 36

May 23, 2017: Sylvester Associate Director Receives USD 2.5 Million Grant for Predictive Testing of Ocular Melanoma 37

Apr 04, 2017: USD 3.6 million to fund personalized 3-D brain maps to guide neurosurgeries 38

Mar 14, 2017: NCI Selects ATCC To Provide End-To-End Cancer Epidemiology Services 40

Feb 02, 2017: Protagen join forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

National Cancer Institute US, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment, Deals by Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Medical Equipment, Deals by Market, 2012 to YTD 2018 8


List Of Table

List of Tables

National Cancer Institute US, Medical Equipment, Key Facts 2

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

National Cancer Institute US, Medical Equipment, Deals By Year, 2012 to YTD 2018 5

National Cancer Institute US, Medical Equipment Deals By Type, 2012 to YTD 2018 6

National Cancer Institute US, Medical Equipment, Deals By Region, 2012 to YTD 2018 7

National Cancer Institute US, Deals By Market, 2012 to YTD 2018 8

National Cancer Institute US, Medical Equipment, Deals Summary, 2012 to YTD 2018 9

GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 10

Pandomedx Enters Into Collaboration with National Cancer Institute 11

Immunovia to Enter into Agreement with National Cancer Institute 12

DiaCarta Enters into Agreement with National Cancer Institute 13

OncoTAb Enters into Agreement with National Cancer Institute 14

SeraCare Life Sciences Enters into R&D Agreement with National Cancer Institute 15

CvergenX Enters Into Co-Development Agreement With National Cancer Institute 16

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 17

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 18

National Cancer Institute US, Key Competitors 19

National Cancer Institute US, Key Employees 20

National Cancer Institute US, Other Locations 22

National Cancer Institute US, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

National Cancer Institute US, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.